Merck & Co. Inc. (MRK)

$99.86

+2.42

(+2.48%)▲

Market is closed - opens 8 PM, 22 Nov 2024
star icon

Merck & Co Inc is a pharmaceutical company that develops and sells prescription drugs in various therapeutic areas, including oncology, vaccines, and infectious diseases.

Performance

  • $97.03
    $100.38
    $99.86
    downward going graph

    2.83%

    Downside

    Day's Volatility :3.34%

    Upside

    0.52%

    downward going graph
  • $94.48
    $134.63
    $99.86
    downward going graph

    5.39%

    Downside

    52 Weeks Volatility :29.82%

    Upside

    25.83%

    downward going graph

Returns

PeriodMerck & Co. Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-16.02%
-7.6%
6.2%
6 Months
-25.48%
-2.3%
8.9%
1 Year
-4.67%
10.1%
23.7%
3 Years
19.35%
7.5%
21.9%

Highlights

Market Capitalization
244.2B
Book Value
$17.58
Dividend Share
3.04
Dividend Yield
3.19%
Earnings Per Share (EPS)
4.78
PE Ratio
20.2
PEG Ratio
0.07
Wall Street Target Price
131.08
Profit Margin
19.23%
Operating Margin TTM
26.2%
Return On Assets TTM
10.53%
Return On Equity TTM
28.33%
Revenue TTM
63.2B
Revenue Per Share TTM
24.93
Quarterly Revenue Growth YOY
4.3999999999999995%
Gross Profit TTM
42.1B
EBITDA
22.9B
Diluted Eps TTM
4.78
Quarterly Earnings Growth YOY
-0.33
EPS Estimate Current Year
7.74
EPS Estimate Next Year
9.48
EPS Estimate Current Quarter
1.5
EPS Estimate Next Quarter
1.89

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 31 Wall street analysts offering stock ratings for Merck & Co. Inc.(by analysts ranked 0 to 5 stars)
Based on 31 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
27
27
27
Hold
4
5
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 31.26%

Current $99.86
Target $131.08

Company Financials

FY18Y/Y Change
Revenue
42.3B
↑ 5.41%
Net Income
6.2B
↑ 142.21%
Net Profit Margin
14.71%
↑ 8.31%
FY19Y/Y Change
Revenue
46.8B
↑ 10.75%
Net Income
9.8B
↑ 58.25%
Net Profit Margin
21.01%
↑ 6.3%
FY20Y/Y Change
Revenue
41.5B
↓ 11.36%
Net Income
7.1B
↓ 28.2%
Net Profit Margin
17.02%
↓ 3.99%
FY21Y/Y Change
Revenue
48.7B
↑ 17.31%
Net Income
13.0B
↑ 84.65%
Net Profit Margin
26.79%
↑ 9.77%
FY22Y/Y Change
Revenue
59.3B
↑ 21.72%
Net Income
14.5B
↑ 11.27%
Net Profit Margin
24.49%
↓ 2.3%
FY23Y/Y Change
Revenue
60.1B
↑ 1.4%
Net Income
365.0M
↓ 97.49%
Net Profit Margin
0.61%
↓ 23.88%
Q2 FY23Q/Q Change
Revenue
15.0B
↑ 3.78%
Net Income
-6.0B
↓ 311.8%
Net Profit Margin
-39.74%
↓ 59.21%
Q3 FY23Q/Q Change
Revenue
16.0B
↑ 6.17%
Net Income
4.7B
↓ 179.41%
Net Profit Margin
29.73%
↑ 69.47%
Q4 FY23Q/Q Change
Revenue
14.6B
↓ 8.34%
Net Income
-1.2B
↓ 125.84%
Net Profit Margin
-8.38%
↓ 38.11%
Q1 FY24Q/Q Change
Revenue
15.8B
↑ 7.83%
Net Income
4.8B
↓ 488.42%
Net Profit Margin
30.19%
↑ 38.57%
Q2 FY24Q/Q Change
Revenue
16.2B
↑ 2.42%
Net Income
5.5B
↑ 14.55%
Net Profit Margin
33.76%
↑ 3.57%
Q3 FY24Q/Q Change
Revenue
16.7B
↑ 3.1%
Net Income
3.2B
↓ 42.13%
Net Profit Margin
18.95%
↓ 14.81%
FY18Y/Y Change
Total Assets
82.6B
↓ 5.96%
Total Liabilities
55.8B
↑ 4.6%
FY19Y/Y Change
Total Assets
84.4B
↑ 2.13%
Total Liabilities
58.4B
↑ 4.74%
FY20Y/Y Change
Total Assets
91.6B
↑ 8.52%
Total Liabilities
66.2B
↑ 13.34%
FY21Y/Y Change
Total Assets
105.7B
↑ 15.4%
Total Liabilities
67.4B
↑ 1.89%
FY22Y/Y Change
Total Assets
109.2B
↑ 3.28%
Total Liabilities
63.1B
↓ 6.43%
FY23Y/Y Change
Total Assets
106.7B
↓ 2.28%
Total Liabilities
69.0B
↑ 9.41%
Q2 FY23Q/Q Change
Total Assets
104.5B
↓ 3.09%
Total Liabilities
65.7B
↑ 7.94%
Q3 FY23Q/Q Change
Total Assets
106.7B
↑ 2.16%
Total Liabilities
65.4B
↓ 0.46%
Q4 FY23Q/Q Change
Total Assets
106.7B
↓ 0.05%
Total Liabilities
69.0B
↑ 5.52%
Q1 FY24Q/Q Change
Total Assets
105.8B
↓ 0.77%
Total Liabilities
65.4B
↓ 5.24%
Q2 FY24Q/Q Change
Total Assets
112.6B
↑ 6.41%
Total Liabilities
69.0B
↑ 5.44%
Q3 FY24Q/Q Change
Total Assets
104.0B
↓ 7.7%
Total Liabilities
73.0B
↑ 5.78%
FY18Y/Y Change
Operating Cash Flow
10.9B
↑ 69.41%
Investing Cash Flow
4.3B
↑ 61.03%
Financing Cash Flow
-13.2B
↑ 31.52%
FY19Y/Y Change
Operating Cash Flow
13.4B
↑ 23.05%
Investing Cash Flow
-2.6B
↓ 160.94%
Financing Cash Flow
-8.9B
↓ 32.67%
FY20Y/Y Change
Operating Cash Flow
10.3B
↓ 23.71%
Investing Cash Flow
-9.4B
↑ 259.19%
Financing Cash Flow
-2.8B
↓ 68.04%
FY21Y/Y Change
Operating Cash Flow
14.1B
↑ 37.61%
Investing Cash Flow
-16.6B
↑ 75.32%
Financing Cash Flow
2.6B
↓ 191.56%
FY22Y/Y Change
Operating Cash Flow
19.1B
↑ 35.34%
Investing Cash Flow
-5.0B
↓ 70.04%
Financing Cash Flow
-9.1B
↓ 451.68%
FY23Y/Y Change
Operating Cash Flow
13.0B
↓ 31.89%
Investing Cash Flow
-14.1B
↑ 183.93%
Financing Cash Flow
-4.8B
↓ 47.25%
Q2 FY23Q/Q Change
Operating Cash Flow
3.7B
↑ 176.62%
Investing Cash Flow
-11.4B
↑ 385.08%
Financing Cash Flow
3.8B
↓ 282.96%
Q3 FY23Q/Q Change
Operating Cash Flow
7.7B
↑ 108.34%
Investing Cash Flow
-334.0M
↓ 97.08%
Financing Cash Flow
-4.3B
↓ 213.6%
Q4 FY23Q/Q Change
Operating Cash Flow
246.0M
↓ 96.81%
Investing Cash Flow
53.0M
↓ 115.87%
Financing Cash Flow
-2.2B
↓ 47.41%
Q1 FY24Q/Q Change
Operating Cash Flow
3.1B
↑ 1156.1%
Investing Cash Flow
-1.4B
↓ 2696.23%
Financing Cash Flow
-2.8B
↑ 25.35%

Technicals Summary

Sell

Neutral

Buy

Merck & Co. Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Merck & Co. Inc.
Merck & Co. Inc.
-8.37%
-25.48%
-4.67%
19.35%
14.02%
Eli Lilly And Company
Eli Lilly And Company
-16.85%
-6.2%
27.14%
189.28%
556.57%
Johnson & Johnson
Johnson & Johnson
-5.97%
1.24%
1.32%
-4.13%
12.22%
Novo Nordisk A/s
Novo Nordisk A/s
-10.28%
-22.11%
2.42%
89.28%
289.6%
Abbvie Inc
Abbvie Inc
-10.07%
2.96%
20.93%
45.06%
93.9%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Merck & Co. Inc.
Merck & Co. Inc.
20.2
20.2
0.07
7.74
0.28
0.11
0.03
17.58
Eli Lilly And Company
Eli Lilly And Company
78.72
78.72
0.69
13.16
0.65
0.14
0.01
15.83
Johnson & Johnson
Johnson & Johnson
25.45
25.45
0.92
9.96
0.21
0.08
0.03
29.14
Novo Nordisk A/s
Novo Nordisk A/s
34.03
34.03
1.53
22.7
0.89
0.21
0.01
27.07
Abbvie Inc
Abbvie Inc
57.94
58.04
0.4
10.94
0.56
0.08
0.04
3.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$244.3B
14.02%
20.2
19.23%
Eli Lilly And Company
Eli Lilly And Company
Buy
$692.7B
556.57%
78.72
20.48%
Johnson & Johnson
Johnson & Johnson
Buy
$370.8B
12.22%
25.45
16.74%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$472.8B
289.6%
34.03
35.01%
Abbvie Inc
Abbvie Inc
Buy
$293.8B
93.9%
57.94
9.22%

Insights on Merck & Co. Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 14.63B → 16.65B (in $), with an average increase of 4.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 5.45B → 3.15B (in $), with an average decrease of 42.1% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 27.1% return, outperforming this stock by 31.8%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 189.0% return, outperforming this stock by 168.3%

Institutional Holdings

  • Vanguard Group Inc

    9.88%

  • BlackRock Inc

    8.19%

  • State Street Corp

    4.64%

  • Morgan Stanley - Brokerage Accounts

    3.34%

  • Wellington Management Company LLP

    2.87%

  • Geode Capital Management, LLC

    2.25%

Corporate Announcements

  • Merck & Co. Inc. Dividends March,2024

    In the quarter ending March,2024. Merck & Co. Inc. has declared dividend of $0.77

    Read More

Company Information

Merck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co. Inc. has a market cap of $297.5 Billion. It has a P.E ratio of 21.66. The shares of Merck & Co. Inc. are trading at $96.54. .

Organization
Merck & Co. Inc.
Employees
70000
CEO
Mr. Robert M. Davis J.D.
Industry
Health Technology

FAQs